Skip to main content

Table 1 Patient characteristics

From: Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

Characteristics (n = 88)
Age (years, mean ± SD) 69.4 ± 8.8
Sex, n (%)
 male 74 (84)
 female 14 (16)
Smoking status, n (%)
 never smoker 10 (11)
 smoker (current or former) 78 (89)
ECOG PS, n (%)
 0–1 75 (85)
 2–4 13 (15)
Histology, n (%)
 Squamous 24 (27)
 Non-squamous 64 (73)
Stage, n (%)
 III B 21 (24)
 IV 67 (76)
EGFR, n (%)
 mutant 3 (3)
 wild type 78 (89)
 not investigated 7 (8)
ALK, n (%)
 rearranged 0
 not rearranged 80 (91)
 not investigated 8 (9)
Number of metastatic organs, n (%)
  < 3 72 (82)
  ≥ 3 16 (18)
Metastatic organs, n (%)
 Pleural effusion or dissemination 21 (24)
 Bone 26 (30)
 Brain 11 (13)
 Adrenal grand 14 (16)
 Liver 14 (16)
  1. ALK anaplastic lymphoma kinase, ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor receptor, SD standard deviation
\